Despite current trends that indicate increasing incidence, acute myocardial infarction remains an uncommon event in pregnant women, yet an important contributor to perinatal morbidity and mortality. Diagnosis and treatments represent a complex challenge during pregnancy, and timeliness and coordination of both are critical. This article reviews the comprehensive, collaborative approach necessary for management of acute myocardial infarction during pregnancy to optimize outcomes for the woman, neonate, and family. Key Words: acute myocardial infarction, cardiac disease, high-risk obstetrics, pregnancy A cute myocardial infarction (AMI) remains a relatively rare occurrence, estimated to be 6.6 per 100 000 women during pregnancy, yet carries significant risk of perinatal morbidity and mortality.
betes, and chronic hypertension become more prevalent, the incidence of AMI in pregnancy may increase. The purpose of this article is to review care principles for women experiencing AMI in pregnancy.
RISK FACTORS
Risk factors for AMI in pregnant women are the same as the general population and include age greater than 35 years, hypertension, diabetes mellitus, obesity, smoking, and dyslipidemia. 5 The cardiac effects of smoking may be exacerbated during pregnancy because of the increased vascular reactivity effects of estrogen and progesterone. 1 Differences in presentation of AMI between younger and older (>35 years) women are related to differences in pathogenesis. Nonatherosclerotic mechanisms, such as coronary spasm and thrombosis, are most commonly reported in younger women, while atherosclerotic disease is more common in older women. 6 The presence of other risk factors such as diabetes, hypertension, hyperlipidemia, and oral contraceptive use is also more prevalent in older women. Women older than 35 years are at greatest risk for AMI in pregnancy or postpartum with cases occurring in women ranging from 16 to 45 years of age. [6] [7] [8] Other risk factors for AMI in pregnancy are thrombophilias, including a history of thrombosis and antiphospholipid syndrome, pregnancy complications such as blood transfusion and postpartum infections, migraines, preeclampsia, collagen diseases, and cocaine use. 1, 5, 7 Systemic vasospasm and endothelial damage from preeclampsia can contribute to coronary artery ischemia. 1 Increased cardiac work resulting from postpartum hemorrhage may predispose a woman to AMI because of increased myocardial oxygen demand or coronary artery thrombosis secondary to compensatory hypercoagulability. Vascular inflammation associated with infection has been associated with increased risk for AMI, but this higher risk is more closely linked with chronic conditions as opposed to acute infection. 1 Cocaine may precipitate an ischemic event by causing systemic and/or coronary artery vasoconstriction. 4 Whether pregnancy alone is a risk factor for AMI is unclear. 9 Increased plasma volume and cardiac output in pregnancy may contribute to coronary ischemia and AMI. The hypercoagulability of pregnancy may predispose some women to thrombotic events. The hemodynamic and physiologic changes during pregnancy are most pronounced in the third trimester with most AMIs occurring during this time. 8 
ETIOLOGIES
The most common cardiac etiologies of maternal death are aortic dissection and AMI. 10 One cause of AMI in pregnancy is atherosclerosis, with or without intracoronary thrombus, but less often than the general population. Nonatherosclerotic causes include coronary artery spasm, coronary artery dissection, thrombus/embolism in a normal coronary artery, arteritis, and in situ thrombosis from thrombophilias. 4, 8 
PHYSIOLOGIC CHANGES Pregnancy, labor, and birth
There are substantial physiologic changes in the cardiovascular system during pregnancy, labor, birth, and into the postpartum period to meet the metabolic demands of both the pregnant woman and fetus. Knowledge and understanding of these changes are necessary to understand the pathophysiology and management principles of AMI in the pregnant woman. Increases in heart rate, blood volume, and stroke volume with resultant increased cardiac output intensify maternal myocardial demand for oxygen. Expected dilutional anemia and decreased diastolic blood pressure during pregnancy may affect myocardial oxygen delivery. During labor and birth, pain, anxiety, and uterine contractions increase oxygen consumption. Dramatic fluid shifts in maternal circulation after birth from relief of aorticvenal compression and loss of the placenta contribute to increased hemodynamic load. Pregnancy is a hypercoagulable state. Factors V, VII, VIII, IX, X, XII; prothrombin; and fibrinogen are increased, whereas the fibrinolytic system is depressed. This alteration in coagulation has implications for management with thrombolytic therapy.
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Pathophysiology of AMI
In an acute myocardial event, the damage to the heart muscle depends upon a number of factors: (1) the number of vessels and branches involved, (2) disease within the vessels, (3) the area(s) of myocardium supplied by the affected vessel(s), (4) the amount of collateral circulation to provide alternative perfusion to the affected region, and (5) the oxygen demands on the heart during and after the infarction. 11 Myocardial oxygenation is maintained through physiologic mechanisms to ensure appropriate coronary perfusion pressure, adequate volumes of oxygenated blood, and unobstructed coronary flow. When one or all of these mechanisms are challenged, myocardial ischemia may occur, yet a substantial deficit must exist before there is presentation of symptoms. A major coronary vessel has typically lost 70% in diameter before angina occurs. 12 As such, the presence of angina is an indicator of significant myocardial ischemia, tissue damage, and cellular death.
Oxygen consumption is determined by the metabolic rate; however, vascular diseases compromise the ability to deliver an adequate amount of oxygen for cellular metabolism. Oxygen delivery is not only dependent upon cardiac output (heart rate multiplied by stroke volume), but also by the oxygen-carrying capacity of the blood and the ability of the lungs to exchange respiratory gases. Tissues increase the rate of oxygen extraction in the presence of reduced oxygen delivery. Once limits of extraction are reached, tissues rely on anaerobic glycolysis for energy and release lactate as a metabolic by-product. Episodes of prolonged oxygen deprivation produce metabolic acidosis, followed by permanent tissue damage.
Myocardial tissue is perfused by the coronary arteries during ventricular diastole, which are dependent upon vascular distensibility and left ventricular function to maintain perfusion pressure. Atherosclerotic plaques from cholesterol deposits and platelet aggregation, hypertension, dissection, or coronary artery vasospasm decrease vascular distensibility. Reduced vascular distensibility contributes to increased energy expenditure in the left ventricle. In the presence of a chronic condition, ventricular hypertrophy may result. Ventricular hypertrophy and associated increased muscle mass increase ventricular stroke work, heart rate, and myocardial oxygen demand. Complications arising from AMI are presented in Table 1 .
DIAGNOSIS
Diagnosis of AMI can be made on the basis of clinical presentation of ischemic symptoms supported by serial electrocardiograms (ECG) and evaluation of cardiac troponins. Diagnosis of AMI during pregnancy may be confounded with the low index of suspicion in childbearing women. 
Electrocardiography
Electrocardiographic readings are a critical tool for AMI assessment and diagnosis. Electrocardiogram leads provide a graphic representation of electrical activity in the heart and reflect changes according to the site of infarction. Note that physiologic changes of pregnancy affect ECG readings, and understanding these changes is essential for correct diagnosis. The gravid uterus displaces the diaphragm upward during the third trimester, causing a left or right axis deviation. Other normal ECG findings in pregnancy include Q waves in lead III, T wave inversion, or an increased R/S ratio in leads V 1 and V 2 .
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ECG findings of ST elevation or depression and inverted Q waves are indicative of ischemic changes.
The ECG findings reveal two groups of AMI: those with ST-segment elevation myocardial infarction (STEMI) and those with non-ST-segment elevation myocardial infarction (NSTEMI) (see Table 2 ). This distinction guides treatment strategies. Coronary artery dissection and coronary artery spasm are more uncommon causes of AMI in the general population, while AMI attributed to atherosclerotic causes is less common in pregnant women. Clinical presentation does not generally differ between the two, and the diagnostic approach is the same for all acute coronary syndromes. 14 Although uncommon, some women with documented AMI will have a normal ECG as evolution of the infarction may occur over the initial 48 hours. 
Chemical biomarkers
Uterine contractions can cause significant increases in cardiac markers such as myoglobin and serum creatinine kinase MB; therefore, troponins are recommended for diagnosis of myocardial injury in pregnant women. 15 Cardiac troponins I and T are sensitive and specific biochemical markers released from injured cardiac muscle. Elevation of troponins indicates myocardial tissue necrosis. Serum blood levels of troponins can be detected 4 to 6 hours after symptom onset from myocardial injury. However, levels may not be detectable soon after AMI; thus, diagnosis is not ruled out in the presence of strong clinical suspicion. 7 Once elevated, troponin I levels will stay elevated for 1 to 2 weeks. 7 Unlike other laboratory values, troponin I is never increased above the upper normal limit in healthy pregnant women. The immediate postpartum period, anesthesia, and even surgical birth do not affect values and elevation is always considered abnormal. 7, 15 Other conditions that might lead to elevated troponins include myocarditis, pericarditis, sepsis, and elevated pressures in the ventricles such as pulmonary embolism and hypertension. Reference ranges for troponin I may vary according to laboratory and method of measurement.
ACUTE COLLABORATIVE MANAGEMENT
Principles of AMI management do not generally differ in pregnancy and require a coordinated, collaborative approach to management. Obstetrics, cardiology, anesthesia, and nursing services are involved in planning and care delivery for the pregnant woman with AMI. Perinatal nursing plays a key role in maintaining team awareness of the physiologic changes in pregnancy that alter target hemodynamic and respiratory values and in planning for fetal assessment and intervention. 11 Management, care setting, and transport decisions are individualized on the basis of maternal and fetal considerations, risks and benefits to both, and etiology of the infarction. Early therapy is focused on several goals: (1) relief of pain and anxiety, (2) reperfusion of affected vessels, (3) improving the balance between myocardial oxygen supply and demand, (4) initiation of antithrombotic therapy to prevent the formation of a secondary thrombus, (5) improving ventricular function, and (6) limiting the infarction size.
11 Timely recognition and treatment are the key to minimizing myocardial damage and optimizing maternal and fetal outcomes. Initial care measures include ensuring a patent airway, oxygen administration, peripheral intravenous access, laboratory analysis of electrolytes, hemoglobin and cardiac enzymes, Foley catheter placement, interventional therapy, and pharmacologic therapy to maintain hemodynamic and rhythm stability. STEMI and NSTEMI are managed differently because of the significance of vessel occlusion.
ST-segment elevation myocardial infarction
Women with complete vessel occlusion (STEMI) must undergo early revascularization by either intravenous thrombolytics or percutaneous coronary intervention (PCI) with stent placement. With PCI, imaging of coronary arteries is completed using contrast media, with placement of stents in affected vessels as indicated. There are two types of stents: bare metal and drugeluting. Bare metal stents are endothelialized earlier, preventing early thrombosis. Drug-eluting stents release antiproliferative medications that decrease risk of restenosis, but delay endothelialization, requiring additional and prolonged antiplatelet therapy. In pregnancy, bare metal stents are generally preferred. 16 Complications of PCI with stent placement include arterial embolization, contrast toxicity, arrhythmia, and vascular injury. In addition, there may be concerns about timing/mode of birth, anesthesia options, and increased risk of hemorrhage due to risks of anticoagulation after stent placement. These risks may be managed with platelet transfusion and use of narcotics or general anesthesia for pain relief if birth is unavoidable. There is an increasing trend toward stent placement as opposed to coronary artery bypass graft surgery for AMI in active labor due to the minimally invasive approach. 16 Percutaneous coronary intervention is the preferred treatment, but if the institution is not capable of performing the procedure, the woman may be treated with recombinant tissue plasminogen activator (r-TPA). Systemic thrombolysis may be used during pregnancy in the absence of absolute contraindications including history of intracranial hemorrhage, ischemic stroke in the last 3 months, head trauma in the last 3 months, brain arterioventricular malformations or neoplasms, suspected aortic dissection, active bleeding or known bleeding disorder, major trauma, bleeding, or surgery in the last 3 weeks, severe uncontrolled hypertension, and neurosurgery in the last 3 months. 7 Relative contraindications include current use of anticoagulants and cardiopulmonary resuscitation for more than 10 minutes. Women who have received thrombolytics should not undergo any operative procedures for 10 days after administration. Thus, obstetric management decision may be complicated if the fetus is viable at or near the time of thrombolytic therapy. The use of thrombolytics also creates concern about allergic reactions, fibrinolytic effects on placental implantation, activation of circulating plasminogen as a trigger of preterm labor, and the development of reperfusion arrhythmias. 4, 17 Prior to stent placement, women with STEMI are managed following similar principles that guide NSTEMI care.
Non-ST-segment elevation myocardial infarction
Treatment of NSTEMI is guided by risk stratification from assessment findings at presentation. Women with NSTEMI who present with cardiogenic shock, overt heart failure, persistent and recurrent rest angina despite medical interventions, hemodynamic instability, or with unstable ventricular arrhythmias are considered very high risk and are usually referred for coronary angiography without delay for further risk stratification. Risk assessment using reliable and established scoring tools such as the Thrombolysis in Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) allows for identification of women who are at risk for failure of medical treatment. Risk scores are calculated from items such as age, vital signs, history, risk factors, current and recent symptoms, laboratory values, and ECG findings. Women with lower risk benefit from intensive medical treatments, while women with higher risk status benefit from early (24-48 hours of admission) coronary angiography and potential revascularization. 
GENERAL TREATMENT PRINCIPLES
Initial care measures for pregnant women with AMI include oxygen administration and pain management. Oxygen is usually initiated at 2-3 L/min per nasal cannula and titrated to optimize oxygenation status. Pain management is essential to reduce oxygen utilization and optimize oxygen delivery to the myocardium. Morphine sulfate, given for pain relief and to reduce anxiety, is considered safe and effective but may cause neonatal respiratory depression if administered shortly before birth.
In addition to pain management and oxygen administration, an understanding of safe medication management to improve maternal outcomes while limiting fetal effects is necessary. Nitrates are frequently administered to relieve ischemic chest pain and decrease myocardial oxygen consumption, as they act to reduce coronary vasospasm and ventricular preload. Nitrates may limit the area of damaged tissue when administered during AMI, but are titrated to avoid maternal hypotension, placental hypoperfusion, and precipitation of nonreassuring fetal status. 4 In women with AMI, β-Adrenergic and β 1-selective blocking agents are utilized for their antihypertensive, anti-ischemic, and antiarrhythmic properties. They act to reduce chest pain, myocardial wall stress, and infarction size. Other antiarrhythmics such as digoxin, quinidine, and adenosine may be used if AMI is complicated by supraventricular and/or ventricular arrhythmias. However, amiodarone HCl is used only in the case of drug-refractory or potentially lethal arrhythmias because of the potential for fetal bradycardia, congenital goiter, and hypothyroidism. 16 Although commonly used for treatment of AMI in the general population, angiotensin-converting enzyme inhibitors are contraindicated in pregnancy because of potential for major congenital malformations in the first trimester and neonatal renal dysfunction in the second and third trimesters. 7 Therefore, alternative medications for vasodilation and blood pressure management, such as nitrates, are recommended. Statins are also used for AMI in the general population for their anti-inflammatory and antioxidant properties, but there is insufficient data to support use in pregnancy. 7 Anticoagulation is a hallmark of AMI treatment to prevent systemic or venous thromboembolism, with two platelet aggregation blockers, aspirin and clopidogrel, most commonly used in the general population and pregnant women. 7 The combination decreases the number of cardiovascular events by 20%. 7 Antiplatelet therapy is used alongside antithrombotic therapy. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are the most commonly used agents. Unfractionated heparin and LMWH do not cross to the placenta, and the effects are easily reversed with protamine sulfate. 1 In women at high risk for development of recurrent symptoms, LMWH appears to be more effective. However, in women with a high risk for development of recurrent symptoms and potential early intervention with PCI, UFH is equally effective with fewer bleeding complications. 7 A summary of common pharmacologic treatments for AMI is presented in Table 3 .
OBSTETRIC CONSIDERATIONS
Most maternal deaths occur at the time of or within 2 weeks of AMI. In addition, some data suggest that birth within 2 weeks of AMI is associated with increased risk for recurrent AMI. 8 Therefore, if a woman is beyond the acute phase of an MI postponing birth for 2-3 weeks to allow for cardiac healing is reasonable. However, there are not data regarding optimal gestational age of birth after an AMI. If the woman is determined to be in preterm labor and tocolysis is indicated, magnesium sulfate is preferred and has a neuroprotective fetal effect if given prior to 32 weeks' gestation. Sympathomimetics are not administered because of associated increases in heart rate and myocardial oxygen consumption, and the potential risk of ischemia, even in otherwise healthy women. 13 Timing of birth is carefully considered on the basis of maternal and fetal status, gestational age, and planned management of anticoagulant therapy. Induction of labor and vaginal birth hold many advantages over operative birth, including elimination of surgical risks, dramatic hemodynamic fluctuations, and decreased blood loss. Prior to birth, interprofessional preparation and development of a plan of care assist providers with communication, staffing, medication, and equipment needs for monitoring. Administration of oxytocin during a scheduled induction of labor is safe; however, recommendations include that prepared oxytocin mixtures be diluted to prevent coronary artery spasm and theoretic antidiuretic hormone activity.
2,4,6 Goals of management for the laboring woman anticipating a vaginal birth include reducing cardiac workload and oxygen demands and normalizing the family birth experience. Lateral recumbent positioning is preferred for labor and birth to optimize cardiac output, while enhancing placental perfusion. 4 Shortening the second stage of labor with the laboring-down technique or instrumental assisted birth are recommended to decrease oxygen consumption, fatigue, and the maternal tendency to Valsalva during pushing. 18 Limited, open glottis pushing may be safe if the woman's ejection fraction is at least 40%. 12 Recommended surveillance during labor, birth, and the first 24 hours postpartum includes continuous assessment of blood pressure, pulse, oxygen saturation, ECG, and fetal heart rate. 12 Supplemental oxygen administration and adequate pain management during labor and birth are essential to minimize myocardial oxygen consumption and increases in cardiac output demand with sudden catecholamine release. Neuraxial anesthesia for pain relief is considered preferable as general anesthesia may be associated with significant increases in blood pressure during intubation. 13 Tachycardia and abnormal blood pressure parameters can have adverse effects on the woman's condition by decreasing cardiac output and should therefore be prevented or corrected if they occur. 4 The use of ergonovines in the postpartum period is avoided because of the risk for coronary artery spasm. 4 An example of interprofessional plan of care is outlined in Table 4 .
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OBSTETRIC ADVANCED CARDIAC LIFE SUPPORT
In the event that cardiopulmonary resuscitation is required following AMI, recommended algorithms and medications are the same as for the nonpregnant patient population. Chest compressions and artificial respirations may be less effective in the pregnant woman owing to the displacement of abdominal contents and elevation of the diaphragm in the second and third trimesters. 2 Modifications to improve cardiac output and manage the woman's airway and emergent perimortem cesarean birth are summarized in Table 5 . [19] [20] [21] [22] [23] Initiation of a perimortem cesarean birth has been advocated within 4 minutes if maternal resuscitation efforts have failed to return a pulse. 19 By relieving aorta and venacaval compression, venous return and subsequent cardiac output may improve, increasing the potential for maternal and fetal survival. Emptying the uterus also improves the effectiveness of chest compressions and autotransfusion increases intravascular volume after birth, improving cardiac output. 22, 23 Neonatal survival is directly proportional to the timing between maternal cardiopulmonary arrest and birth. 20 Delivery of the fetus within 5 minutes significantly improves the neurologically intact survival rate of the viable fetus. 20 Cessation of maternal cerebral blood flow occurs at 6 minutes, and fetal survivability decreases with each minute after maternal cardiac arrest. However, there are case reports of maternal cardiac arrest outside of the acute hospital setting with perimortem cesarean section performed as late as 26-35 minutes after arrest yielding a neonatal survival rate of 25%. 20, 21 To reflect the benefits of early cesarean birth, a mindset and terminology change from perimortem cesarean section to resuscitative hysterotomy has been recommended. 22 Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 10 Baird and Kennedy, 11 and Lipman et al. 23 The obstetric nurse is a key member of the resuscitation team and potentially fulfills several roles in the event of a maternal cardiac arrest. These may include the historian to provide pivotal patient information regarding pregnancy and maternal assessment prior to arrest, administration of emergency medications, intravenous insertion, documentation of code events, and providing chest compressions. Further recommendations include practice with simulated code scenarios for all team members on a routine basis.
PREGNANCY AFTER AMI
Pregnancy after AMI is associated with increased incidence of short-and long-term illness, rather than high maternal mortality. 4 The amount of residual cardiac function, anatomy, and cause of initial infarction determine maternal morbidity. Testing to determine evidence of coronary vascular disease and myocardial function is advised before future pregnancy. Women are typically advised to wait at least 1 year following an AMI before becoming pregnant again. Because episodic myocardial ischemia may be occurring without angina, treadmill exercise tolerance testing and myocardial perfusion imaging at rest and after peak exercise is recommended. If treadmill testing reveals abnormal response, angina, or a drop in blood pressure at a low level of exercise, the woman is at high risk for a serious and/or fatal myocardial ischemic event and is advised against becoming pregnant. Coronary arteriography may be also performed to determine degree of coronary stenoses and potential need for revascularization. Myocardial infarction can cause left ventricular damage, resulting in decreased cardiac contractility and cardiac output. Therefore, left ventricular function studies such as echocardiography or transesophageal echocardiography are performed prior to a future pregnancy. If severe damage, decreased left ventricular function, and heart failure are present, women are strongly advised against further childbearing.
of maternal symptoms such that diagnostic testing and treatment may be rapidly initiated to preserve myocardial functioning. The perinatal nurse plays a key role in planning and caring for the woman experiencing AMI during pregnancy. Team and interprofessional communication is essential for providing safe, accurate, patientcentered care to achieve optimal maternal and fetal outcomes.
